Detailed videocapillaroscopic microvascular changes detectable in adult COVID-19 survivors.
COVID-19
Capillaries
Endothelial cells
Glucocorticoids
Microcirculation
Nailfold capillaroscopy
Raynaud's phenomenon
SARS-CoV-2
Journal
Microvascular research
ISSN: 1095-9319
Titre abrégé: Microvasc Res
Pays: United States
ID NLM: 0165035
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
03
01
2022
revised:
08
03
2022
accepted:
14
03
2022
pubmed:
28
3
2022
medline:
7
6
2022
entrez:
27
3
2022
Statut:
ppublish
Résumé
COVID-19 is a multisystem disease that causes endothelial dysfunction and organ damage. Aim of the study was to evaluate the microvascular status in COVID-19 survivors with past different disease severity, in comparison with age and sex-matched primary Raynaud's phenomenon (PRP) patients and control subjects (CNT), including possible effects of concomitant therapies. Sixty-one COVID-19 survivors (mean age 58 ± 13 years, mean days from disease onset 126 ± 53 and mean days from recovery 104 ± 53), thirty-one PRP patients (mean age 59 ± 15 years, mean disease duration 11 ± 10 years) and thirty CNT (mean age 58 ± 13 years) underwent nailfold videocapillaroscopy (NVC) examination. The following capillaroscopic parameters were searched and scored (0-3): dilated capillaries, giant capillaries, isolated microhemorrhages, capillary ramifications (angiogenesis) and capillary number, including absolute capillary number per linear millimeter at the nailfold bed. The mean nailfold capillary number per linear millimeter was significantly lower in COVID-19 survivors when compared with PRP patients and CNT (univariate and multivariate analysis p < 0.001). On the contrary, COVID-19 survivors showed significantly less isolated microhemorrhages than PRP patients and CNT (univariate and multivariate analysis, p = 0.005 and p = 0.012, respectively). No statistically significant difference was observed between COVID-19 survivors and control groups concerning the frequency of dilated capillaries and capillary ramifications. COVID-19 selective therapies showed a promising trend on preserving capillary loss and deserving further investigations. SARS-CoV-2 seems to mainly induce a significant loss of capillaries in COVID-19 survivors at detailed NVC analysis in comparison to controls. The presence of a significant reduced score for isolated microhaemorrhages in COVID-19 survivors deserves further analysis.
Identifiants
pubmed: 35339493
pii: S0026-2862(22)00051-6
doi: 10.1016/j.mvr.2022.104361
pmc: PMC8942583
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104361Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
Respiration. 2022;101(2):155-165
pubmed: 34525475
Microvasc Res. 2021 Nov;138:104196
pubmed: 34097919
J Crit Care. 2021 Feb;61:73-75
pubmed: 33096349
Microvasc Res. 2021 Jan;133:104071
pubmed: 32949574
RMD Open. 2020 Dec;6(3):
pubmed: 33372031
Clin Exp Optom. 2022 Nov;105(8):848-852
pubmed: 34875203
Rheumatology (Oxford). 2021 Jan 5;60(1):e19-e20
pubmed: 32940700
Cardiovasc Drugs Ther. 2022 Jun;36(3):547-560
pubmed: 34097193
Clin Exp Rheumatol. 1992 Sep-Oct;10(5):485-8
pubmed: 1458701
Front Cardiovasc Med. 2021 Jun 11;8:687783
pubmed: 34179146
RMD Open. 2021 Mar;7(1):
pubmed: 33790049
Nutrients. 2021 Feb 24;13(3):
pubmed: 33668240
Nat Commun. 2021 Jul 5;12(1):4117
pubmed: 34226537
RMD Open. 2020 May;6(1):
pubmed: 32423970
Microvasc Res. 2021 Mar;134:104119
pubmed: 33278457
Best Pract Res Clin Rheumatol. 2008 Dec;22(6):1093-108
pubmed: 19041079
Clin Exp Optom. 2022 Nov;105(8):842-847
pubmed: 34751081
Autoimmun Rev. 2020 Mar;19(3):102458
pubmed: 31927087
Can J Ophthalmol. 2021 Feb;56(1):24-30
pubmed: 33249111
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919
pubmed: 33389262
Nat Rev Rheumatol. 2021 Nov;17(11):665-677
pubmed: 34561652
Autoimmun Rev. 2019 Nov;18(11):102394
pubmed: 31520797
Atherosclerosis. 2020 Dec;314:58-62
pubmed: 33161318
Angiogenesis. 2021 Feb;24(1):145-157
pubmed: 33058027
Am J Ophthalmol. 2021 Jul;227:182-190
pubmed: 33781767
Basic Res Cardiol. 2021 Jul 5;116(1):42
pubmed: 34224022
Lancet Rheumatol. 2021 Mar;3(3):e224-e233
pubmed: 33521655
Ann Rheum Dis. 2008 Jun;67(6):885-7
pubmed: 18037628
Chest. 2020 Dec;158(6):e267-e268
pubmed: 32622823
Reumatismo. 2013 Oct 31;65(4):186-91
pubmed: 24192563